Volume 30, Issue 139 (March & April 2022)                   J Adv Med Biomed Res 2022, 30(139): 185-189 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohammadi-asl J, Shahbazian H, Jasemi Zergani F, Kheradmand A. Identification of a Novel CLCNKB Mutation in an Iranian Family with Bartter Syndrome Type 3.. J Adv Med Biomed Res 2022; 30 (139) :185-189
URL: http://journal.zums.ac.ir/article-1-6189-en.html
Identification of a Novel CLCNKB Mutation in an Iranian Family with Bartter Syndrome Type 3.
Javad Mohammadi-asl * 1, Heshmatolah Shahbazian2 , Farzad Jasemi Zergani3 , Alireza Kheradmand4
1- NoorGene Genetic Lab, Ahvaz, Iran , mohammadi-asl@ajums.ac.ir
2- Dept. of the Pediatrics, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3- Dept. of Internal Medicine, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4- Dept. of Urology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Abstract:   (92476 Views)

Bartter syndrome (BS) is a group of uncommon genetic disorders of reabsorption of salt in the cortical thick ascending limb (TAL) of the Henle's loop, typically distinguished by metabolic alkalosis, salt loss, hypokalemia, hyperreninemic hyperaldosteronism and normal blood pressure. Bartter syndrome type 3, recognized as a classic BS (CBS), occurs because of mutations in CLCNKB gene.
We enrolled one consanguineous Iranian family with one patient in our study. Targeted genomic capture and massively parallel sequencing (MPS) of all recognized genes responsible for BS subtypes 1–5 were carried out to recognize the genetic reasons of BS.
Here, we report the recognition of a novel homozygous frameshift mutation in the CLCNKB gene in an Iranian pedigree. The subjects were homozygous for a frameshift mutation (p.Gly662GlyfsX12) within CLCNKB gene that encodes the basolateral chloride voltage-gated channel Kb.
The identification of other causative mutations in CLCNKB gene additionally supports the important function of this gene in causing BS. To the best of our knowledge, this is a novel CLCNKB gene mutation in BS children.The accurate function of the CLCNKB Gly662GlyfsX12 mutation in the CBS pathogenesis  is still unknown.

Keywords: Bartter syndrome, mutation, CLCNKB, Whole exome sequencing
Full-Text [PDF 335 kb]   (47103 Downloads) |   |   Full-Text (HTML)  (1179 Views)  

✅ We enrolled one consanguineous Iranian family with one patient in our study. Targeted genomic captureand massively parallel sequencing (MPS) of all recognized genes responsible for BS subtypes 1–5 were carried out to recognize the genetic reasons of BS. Here, we report the recognition of a novel homozygous frameshift mutation in the CLCNKB gene in an Iranian pedigree. 


Type of Study: Case report | Subject: Medical Biology
Received: 2020/08/26 | Accepted: 2021/03/3 | Published: 2022/01/31
References
1. Cunha TDS, Heilberg IP. Bartter syndrome: causes, diagnosis, and treatment. Int J NephrolRenovasc Dis. 2018;11:291-301. [DOI:10.2147/IJNRD.S155397] [PMID] [PMCID]
2. Yang X, Zhang G, Wang M, Yang H, Li Q. Bartter Syndrome type 3: Phenotype-genotype correlation and favorable response to ibuprofen. Front Pediatr. 2018;6:153. [DOI:10.3389/fped.2018.00153] [PMID] [PMCID]
3. Andrini O, Keck M, Briones R, Lourdel S, Vargas-Poussou R, Teulon J. ClC-K chloride channels: emerging pathophysiology of Bartter syndrome type 3. Am J Physiol Renal Physiol. 2015;308(12):F1324-34. [DOI:10.1152/ajprenal.00004.2015] [PMID]
4. Castaño AG, de Nanclares GP, Madariaga L, et al. Genetics of type III Bartter syndrome in Spain, proposed diagnostic algorithm. PLoS One. 2013;8(9):e74673. [DOI:10.1371/journal.pone.0074673] [PMID] [PMCID]
5. Blackburn AT, Miller RK. Modeling congenital kidney diseases in Xenopuslaevis.Dis Model Mech. 2019;12(4).
6. Zelikovic I, Szargel R, Hawash A, et al. A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes. Kidney Int. 2003;63(1):24-32. [DOI:10.1046/j.1523-1755.2003.00730.x] [PMID]
7. Akil I, Ozen S, Kandiloglu AR, Ersoy B. A patient with Bartter syndrome accompanying severe growth hormone deficiency and focal segmental glomerulosclerosis. ClinExpNephrol. 2010;14(3):278-82. [DOI:10.1007/s10157-009-0262-7] [PMID]
8. Zhu B, Jiang H, Cao M, Zhao X, Jiang H. A novel CLCNKB mutation in a Chinese girl with classic Bartter syndrome: a case report. BMC Med Genet. 2019;20(1):1-6. [DOI:10.1186/s12881-019-0869-9] [PMID] [PMCID]
9. Gil-Peña H, Garcia-Lopez E, Alvarez-Garcia O, et al. Alterations of growth plate and abnormal insulin-like growth factor I metabolism in growth-retarded hypokalemic rats: effect of growth hormone treatment. Am J Physiol Renal Physiol. 2009;297(3):F639-45. [DOI:10.1152/ajprenal.00188.2009] [PMID]
10. Jentsch TJ, Stein V, Weinreich F, Zdebik AA. Molecular structure and physiological function of chloride channels. Physiol Rev. 2002;82(2):503-68. [DOI:10.1152/physrev.00029.2001] [PMID]
11. Nozu K, Fu XJ, Nakanishi K, et al. Molecular analysis of patients with type III Bartter syndrome: picking up large heterozygous deletions with semiquantitative PCR. Pediatr Res. 2007;62(3):364-9. [DOI:10.1203/PDR.0b013e318123fb90] [PMID]
12. Schlingmann KP, Konrad M, Jeck N, et al. Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med. 2004;350(13):1314-9. [DOI:10.1056/NEJMoa032843] [PMID]
13. Seys E, Andrini O, Keck M, et al. Clinical and genetic spectrum of Bartter syndrome type 3. J Am SocNephrol. 2017;28(8):2540-52. [DOI:10.1681/ASN.2016101057] [PMID] [PMCID]
14. Seyberth HW. An improved terminology and classification of Bartter-like syndromes. Nat ClinPractNephrol. 2008;4(10):560-7. [DOI:10.1038/ncpneph0912] [PMID]
15. Yu Y, Xu C, Pan X, et al. Identification and functional analysis of novel mutations of the CLCNKB gene in Chinese patients with classic Bartter syndrome. Clin Genet. 2010;77(2):155-62. [DOI:10.1111/j.1399-0004.2009.01288.x] [PMID]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb